Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) EPS (Weighted Average and Diluted) (2020 - 2025)

Barinthus Biotherapeutics' EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$0.27 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 47.06% year-over-year to -$0.27; the TTM value through Dec 2025 reached -$1.64, down 5.81%, while the annual FY2025 figure was -$1.64, 5.81% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.27 in Q4 2025 per BRNS's latest filing, up from -$0.36 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.41 in Q2 2022 to a low of -$1.9 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.4, with a median of -$0.42 recorded in 2024.
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 1400.0% in 2021, then soared 269.23% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.38 in 2021, then crashed by 44.74% to -$0.55 in 2022, then grew by 18.18% to -$0.45 in 2023, then dropped by 13.33% to -$0.51 in 2024, then skyrocketed by 47.06% to -$0.27 in 2025.
  • Per Business Quant, the three most recent readings for BRNS's EPS (Weighted Average and Diluted) are -$0.27 (Q4 2025), -$0.36 (Q3 2025), and -$0.52 (Q2 2025).